Pebblebrook Hotel Trust approves 2026 executive compensation, similar to 2025 structure

Pebblebrook Hotel Trust

CEO Jon Bortz: base salary $840K, target cash bonus $1.39M, 62% equity-based target compensation.
CFO Raymond Martz and COO Thomas Fisher each: base $560K, target cash bonus $590K.
Time-based LTIP Units awarded: Bortz 127,369; Martz 56,218; Fisher 56,218 RSUs.
Performance-based units target: Bortz 191,054; Martz & Fisher 84,327 each, vest on TSR metrics.
Cash bonus tied to seven 2026 objectives including Adjusted FFO, dispositions, and hotel EBITDA.

item 5.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001474098-26-000006
form_type: 8-K
ticker: PEB
cik: 0001474098
company_name: Pebblebrook Hotel Trust
filed_at: 2026-02-09T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.148761+00:00
generated_at: 2026-05-16T03:52:28.330369+00:00
sec_items: ["5.02", "9.01"]
event_type: other
sentiment: neutral
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001474098-26-000006
json_url: https://secwatch.observer/filing/0001474098-26-000006.json
markdown_url: https://secwatch.observer/filing/0001474098-26-000006.md
text_url: https://secwatch.observer/filing/0001474098-26-000006.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1474098/000147409826000006/0001474098-26-000006-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1474098/000147409826000006/peb-20260205.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

EDSA

Edesa Biotech shareholders approve equity plan amendment adding 750K shares

Edesa Biotech, Inc. May 29, 2026, 4:15 PM ET other Items 5.02, 5.07, 9.01

same SEC item: 5.02, 9.01 same event type: other similar materiality

Filing page SEC filing

IIIV

i3 Verticals posts Q2 FY2026 presentation for investor conferences; no specific results provided

i3 Verticals, Inc. June 2, 2026, 5:28 PM ET other Items 7.01, 9.01

same SEC item: 9.01 same event type: other similar materiality

Filing page SEC filing

ACIW

ACI Worldwide annual meeting approves all proposals including director elections

ACI WORLDWIDE, INC. June 2, 2026, 5:08 PM ET other Items 5.07, 9.01

same SEC item: 9.01 same event type: other similar materiality

Filing page SEC filing

PSTL

Postal Realty Trust updates non-employee director compensation after 2026 annual meeting

Postal Realty Trust, Inc. June 2, 2026, 5:05 PM ET other Items 5.02

same SEC item: 5.02 same event type: other similar materiality

Filing page SEC filing

VMD

Viemed Healthcare files investor presentation with no material updates

VIEMED HEALTHCARE, INC. June 2, 2026, 5:00 PM ET other Items 7.01, 9.01

same SEC item: 9.01 same event type: other similar materiality

Filing page SEC filing

VFF

Village Farms shareholders elect all seven director nominees and approve advisory say-on-pay at annual meeting

Village Farms International, Inc. June 2, 2026, 5:00 PM ET other Items 5.07, 7.01, 9.01

same SEC item: 9.01 same event type: other similar materiality

Filing page SEC filing

MUX

McEwen announces 2026 Annual Meeting and Bullpen Q&A; no material news

McEwen Inc. June 2, 2026, 4:45 PM ET other Items 7.01, 9.01

same SEC item: 9.01 same event type: other similar materiality

Filing page SEC filing

KYTX

Kyverna Therapeutics shareholders elect Ian Clark and Christi Shaw as Class II directors, ratify BDO USA auditor

Kyverna Therapeutics, Inc. June 2, 2026, 4:30 PM ET other Items 5.07, 9.01

same SEC item: 9.01 same event type: other similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001474098-26-000006

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.